# Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease

> **NCT07417670** · PHASE4 · COMPLETED · sponsor: **Carnot Laboratories** · enrollment: 105 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Memantine
- **DRUG:** Memantine Oral Tablet

## Key facts

- **NCT ID:** NCT07417670
- **Lead sponsor:** Carnot Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-04
- **Primary completion:** 2025-08-12
- **Final completion:** 2025-08-18
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07417670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07417670, "Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07417670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*